These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2080188)

  • 21. Behavioural and biochemical effects of tryptophan, tyrosine and phenylalanine in mice.
    Gibson CJ; Deikel SM; Young SN; Binik YM
    Psychopharmacology (Berl); 1982; 76(2):118-21. PubMed ID: 6805020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentiation of d-amphetamine and L-dopa-induced acoustic startle activity after long-term exposure to amphetamine.
    Kokkinidis L; MacNeill EP
    Psychopharmacology (Berl); 1982; 78(4):331-5. PubMed ID: 6818594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of dietary tyrosine, phenylalanine, and tryptophan on aggression in mice.
    Thurmond JB; Lasley SM; Conkin AL; Brown JW
    Pharmacol Biochem Behav; 1977 Apr; 6(4):475-8. PubMed ID: 560699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Guilingji on brain monoamines and their metabolites in mice.
    Liu JK; Kabuto H; Hiramatsu M; Mori A
    Acta Med Okayama; 1991 Aug; 45(4):217-22. PubMed ID: 1962529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anorexigenic effects of d-amphetamine and l-DOPA in the rat.
    Sanghvi IS; Singer G; Friedman E; Gershon S
    Pharmacol Biochem Behav; 1975; 3(1):81-6. PubMed ID: 1129359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of d-amphetamine and apomorphine upon operant behavior and schedule-induced licking in rats with 6-hydroxydopamine-induced lesions of the nucleus accumbens.
    Robbins TW; Roberts DC; Koob GF
    J Pharmacol Exp Ther; 1983 Mar; 224(3):662-73. PubMed ID: 6402587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of D-amphetamine and L-amphetamine in reversing depression of mouse locomotor activity caused by reserpine.
    Proctor CD; Kirby J; Wood MH; Wade LH; King PK
    Arch Int Pharmacodyn Ther; 1974 Nov; 212(1):108-15. PubMed ID: 4451411
    [No Abstract]   [Full Text] [Related]  

  • 29. Behavioral effects of serotonergic and dopaminergic drugs in cats following chronic amphetamine administration.
    Trulson ME; Crisp T
    Eur J Pharmacol; 1984 Apr; 99(4):313-24. PubMed ID: 6734730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of simultaneous administration of 3,4-dihydroxyphenylpyruvic acid and L-dopa on the bioavailability of L-dopa in rat and mouse.
    Hietala P; Lindén IB; Grönfors N
    J Pharm Pharmacol; 1979 Apr; 31(4):205-8. PubMed ID: 36456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice.
    Törnwall M; Tuomainen P; Männistö PT
    Arch Int Pharmacodyn Ther; 1992; 320():5-20. PubMed ID: 1300941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Behavioral concomitants of regional changes in the brain's biogenic amines after apomorphine and amphetamine.
    Schwarting RK; Huston JP
    Pharmacol Biochem Behav; 1992 Apr; 41(4):675-82. PubMed ID: 1594634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. L-dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice.
    Cooper DR; Marrel C; van de Waterbeemd H; Testa B; Jenner P; Marsden CD
    J Pharm Pharmacol; 1987 Oct; 39(10):809-18. PubMed ID: 2891818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic L-DOPA-pretreatment of rats: an electrophysiological and biochemical study in the basal ganglia.
    Jackson DM; Walters JR; Miller LP
    Brain Res; 1982 Nov; 250(2):271-82. PubMed ID: 6129029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of L-tyrosine on brain monoamines in rats given intravenous amphetamine.
    Smith DG; Geis LS; Lyness WH
    Subst Alcohol Actions Misuse; 1984-1985; 5(6):293-8. PubMed ID: 6085821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylcypromine plus L-DOPA.
    Green AR; Kelly PH
    Br J Pharmacol; 1976 May; 57(1):141-7. PubMed ID: 1276533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
    J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Some effects of prenatal exposure to d-amphetamine sulfate and phenobarbital on developmental neurochemistry and on behavior.
    Zemp JW; Middaugh LD
    Addict Dis; 1975; 2(1-2):307-31. PubMed ID: 1163369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.